Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
-
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Stanford is currently accepting patients for this trial. -
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Stanford is currently accepting patients for this trial. -
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Stanford is currently accepting patients for this trial. -
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Stanford is currently accepting patients for this trial. -
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Stanford is currently accepting patients for this trial.